23073-04-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2,4-bis(4-methoxyphenyl)-4-oxobutanenitrile is used as a key intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs due to its ability to facilitate the construction of complex molecular structures.
Used in Agrochemical Production:
In the agrochemical industry, 2,4-bis(4-methoxyphenyl)-4-oxobutanenitrile serves as an intermediate, playing a crucial role in the synthesis of various agrochemicals that are essential for crop protection and enhancement of agricultural yields.
Used in Research and Development:
2,4-bis(4-methoxyphenyl)-4-oxobutanenitrile is utilized in research and development for the exploration of new drug candidates and the advancement of organic synthesis techniques, thanks to its versatile reactivity and potential for constructing intricate molecular frameworks.
Used in Specialty Chemicals Production:
2,4-bis(4-methoxyphenyl)-4-oxobutanenitrile is also employed in the production of specialty chemicals, where its unique properties and reactivity are harnessed to create high-value chemical products for specific applications.

Upstream product

• 2373-89-9 4,4'-dimethoxychalcone 
• 74-90-8 hydrogen cyanide 
• 41564-67-4 (E)-1,3-bis(4-methoxyphenyl)-2-propene-1-one 
• 151-50-8 potassium cyanide 
• 123-11-5 4-methoxy-benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 23073-06-5 2,4-bis-(4-methoxy-phenyl)-4-oxo-butyric acid methyl ester 

Relevant academic research and scientific papers

Preparation of 3,5-diarylsubstituted 5-hydroxy-1,5-dihydro-2: H -pyrrol-2-ones via base-assisted cyclization of 3-cyanoketones

A convenient preparative method is developed allowing for expeditious assembly of 3,5-diarylsubstituted 5-hydroxy-1,5-dihydro-2H-pyrrol-2-ones from routinely available inexpensive synthetic precursors. These compounds could not be prepared via the previously known protocols, as 2-aminofuran derivatives were produced instead.

Structure-activity relationships in a series of orally active γ- hydroxy butenolide endothelin antagonists

The design of potent and selective non-peptide antagonists of endothelin-1 (ET-1) and its related isopeptides are important tools defining the role of ET in human diseases. In this report we will describe the detailed structure-activity relationship (SAR) studies that led to the discovery of a potent series of butenolide ET(A) selective antagonists. Starting from a micromolar screening hit, PD012527, use of Topliss decision tree analysis led to the discovery of the nanomolar ET(A) selective antagonist PD155080. Further structural modifications around the butenolide ring led directly to the subnanomolar ET(A) selective antagonist PD156707, IC50's = 0.3 (ET(A)) and 780 nM (ET(B)). This series of compounds exhibited functional activity exemplified by PD156707. This derivative inhibited the ET(A) receptor mediated release of arachidonic acid from rabbit renal artery vascular smooth muscle cells with an IC50 = 1.1 nM and also inhibited the ET-1 induced contraction of rabbit femoral artery rings (ET(A) mediated) with a pA2 = 7.6. PD156707 also displayed in vivo functional activity inhibiting the hemodynamic responses due to exogenous administration of ET-1 in rats in a dose dependent fashion. Evidence for the pH dependence of the open and closed tautomerization forms of PD156707 was demonstrated by an NMR study. X- ray crystallographic analysis of the closed butenolide form of PD156707 shows the benzylic group located on the same side of the butenolide ring as the γ- hydroxyl and the remaining two phenyl groups on the butenolide ring essentially orthogonal to the butenolide ring. Pharmacokinetic parameters for PD156707 in dogs are also presented.